title: Weight loss associated with exenatide in an obese man with diabetes commenced on clozapine.
authors.affiliation: School of Medicine, The University of Queensland, Brisbane, QLD, Australia Metro South Addiction and Mental Health Service, Brisbane, QLD, Australia MIRT, MacGregor, QLD, Australia d.siskind@uq.edu.au.
authors.forename: Dan
authors.initials: D
authors.lastname: Siskind
authors.affiliation: School of Medicine, The University of Queensland, Brisbane, QLD, Australia Metro South Addiction and Mental Health Service, Brisbane, QLD, Australia.
authors.forename: Daniel
authors.initials: D
authors.lastname: Wysoczanski
authors.affiliation: School of Medicine, The University of Queensland, Brisbane, QLD, Australia Department of Endocrinology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
authors.forename: Anthony
authors.initials: A
authors.lastname: Russell
authors.affiliation: Metro South Addiction and Mental Health Service, Brisbane, QLD, Australia.
authors.forename: Mark
authors.initials: M
authors.lastname: Ashford
mesh_terms: D000328:Adult; D003024:Clozapine / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced*; D000077270:Exenatide; D006801:Humans; D008297:Male; D010455:Peptides / Q000009:adverse effects*; D012559:Schizophrenia / Q000188:drug therapy*; D014688:Venoms / Q000009:adverse effects*; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D010455:Peptides; D014688:Venoms; D000077270:Exenatide; D003024:Clozapine